Press

Class of 17 Flinn Scholars chooses Arizona universities

Seventeen of Arizona's highest-achieving high-school seniors have decided to attend one of the state's public universities on a Flinn Scholarship. The award includes funding for four years of study, academic-focused travel abroad, mentorship by top faculty, and other benefits. Altogether, the package is worth more than $50,000--on top of the cash value of tuition, provided by the student's chosen university.

Flinn Foundation elects new president and CEO

The Flinn Foundation board of directors has chosen a longtime Arizona leader in health care, education, and public policy as its next president and chief executive officer. Jack B. Jewett, a former president of the Arizona Board of Regents and five-term member of the Arizona House of Representatives, will succeed retiring President and CEO John W. Murphy, who has led the Foundation since 1981. Jewett will assume the position in June.

Arizona’s bioscience sector has substantial economic impact, analysis says

A new analysis of Arizona’s emerging bioscience sector reveals that it has a multibillion-dollar annual economic impact and generates hundreds of millions of dollars in yearly state and local taxes. The study findings will be presented in Phoenix today at Biozona 2009, the annual conference of the Arizona BioIndustry Association. The analysis was performed by […]

Flinn Foundation hires leading executive search firm Spencer Stuart to recruit next CEO

The Flinn Foundation has contracted with executive search firm Spencer Stuart to coordinate the search for its next chief executive. The move was prompted by the announcement of current President & CEO John W. Murphy to retire by June 1, 2009.  Murphy joined the Foundation in 1981 as its executive director and first staff member.

Arizona’s bioscience initiative broadens gains through sixth year

How does Arizona fare six years into its long-term plan to build a thriving biosciences region? In a nutshell, the state has recorded rapid growth well above U.S. norms in generating federal grants and adding new bioscience jobs and firms. But the enduring need for capital investment for young companies continues to be an Achilles heel.

1 2 5 6 7